What is the global market size of Influenza Vaccine Market?

Global Influenza Vaccine Market size was valued at USD 6.81 billion in 2021 and is poised to grow from USD 7.28 billion in 2022 to USD 12.37 billion by 2030, growing at a CAGR of 6.83% in the forecast period (2023-2030).

Influenza Vaccine Market Companies

Influenza Vaccine Market Competitive Landscape

Sanofi, a global leader in the healthcare industry, dominates the influenza vaccine market. Sanofi has a comprehensive vaccine portfolio that includes quadrivalent and trivalent vaccines. By constantly upgrading its technologies, the company focuses on delivering effective vaccines. Other companies, such as CSL Limited, GlaxoSmithKline plc, and AstraZeneca, have effective products that are marketed globally. Furthermore, factors such as increasing efforts to reduce disease burden and rising vaccination rates are the primary focus of market participants.

Influenza Vaccine Market Top Players Company Profiles

Sanofi Pasteur
GlaxoSmithKline
Seqirus (a division of CSL Limited)
AstraZeneca
Pfizer
Merck & Co.
Johnson & Johnson
Novartis
Serum Institute of India
Daiichi Sankyo Company, Limited
Mitsubishi Tanabe Pharma Corporation
Sinovac Biotech Ltd.
Abbott Laboratories
Bavarian Nordic A/S
Hualan Biological Engineering Inc.
BiondVax Pharmaceuticals Ltd.
Medicago Inc.
Altimmune Inc.
Vaxart Inc.
Moderna Inc.

Influenza Vaccine Market

FAQs

Global Influenza Vaccine Market size was valued at USD 7.91 Billion in 2024 and is poised to grow from USD 8.46 Billion in 2025 to USD 14.52 Billion by 2033, growing at a CAGR of 6.98% during the forecast period (2026–2033).

Companies are trying to expand their product pipelines by submitting new molecule applications or expanding the application of current molecules. Other strategies, including as mergers and acquisitions, industry-academia partnership to commercialize more marketed molecules, or sequencing approaches, will also have an impact on current market trends. The research also outlines company-specific product development strategies, market consolidation initiatives, and analyses of their individual strengths, weaknesses, opportunities, and threats. 'Sanofi Pasteur (France)', 'GlaxoSmithKline plc (GSK, UK)', 'Seqirus (CSL, Australia)', 'Pfizer Inc. (USA)', 'AstraZeneca PLC (UK)', 'Novavax, Inc. (USA)', 'Bharat Biotech (India)', 'Johnson & Johnson (USA)', 'Sinovacâ¯Biotech (China)', 'Bioâ¯Farma (Indonesia)', 'Serumâ¯Institute of India (India)', 'Abbottâ¯Biologicals B.V. (Netherlands)', 'Adimmuneâ¯Corporation (Taiwan)', 'BIKEN Co., Ltd. (Japan)', 'Changchunâ¯BCHT Biotechnology (China)', 'Valnevaâ¯SE (France)', 'Scinai Immunotherapeutics Ltd (Israel)', 'Moderna, Inc. (US)', 'Altimmune, Inc. (USA)', 'Osivax (France)'

The increasing government support and surveillance for influenza vaccination is one of the critical and significant factors driving the global market. Surveillance at the national and global levels is required to monitor the supply, distribution, and administration of flu vaccines. WHO, in collaboration with other governments, constantly monitors demand and conducts immunization programmes around the world to reduce the vaccine's requirement in the region. For instance, in year 2021, the Australia government has already vaccinated approximately 5 million people through this immunization programme, and more than 20 million vaccines are still available.

The coronavirus pandemic had an unforeseen impact on routine immunization programmes and campaigns in both developing and developed countries. However, flu vaccination rates have increased significantly during the pandemic due to factors such as increased pressure from health experts/health departments, as well as the extension/expansion of various government programmes that provide free flu vaccination.

In 2021, North America dominated the influenza vaccine market and is anticipated to maintain its dominance throughout the forecast period. Rapid product launches, combined with technologically advanced vaccine manufacturing systems across the region, are expected to drive market growth in the region. Furthermore, rising influenza prevalence and high vaccine sales are expected to fuel market growth in North America. Furthermore, rising government funding, the presence of strong key players, and sophisticated vaccination centres and hospitals will all contribute to the market's stellar growth.

Top Influenza Vaccine Companies

Influenza Vaccine Market Competitive Landscape

FAQs

Request Free Customization

Top Influenza Vaccine Companies

Influenza Vaccine Market Competitive Landscape

FAQs

What is the global market size of Influenza Vaccine Market?

Who are the key vendors in the Influenza Vaccine Market?

What is the key driver of Influenza Vaccine Market?

What is the key market trend for Influenza Vaccine Market?

Which region accounted for the largest share in Influenza Vaccine Market?

Request Free Customization